{"id":"W3037551703","doi":"10.2337/dc20-0120","title":"Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Population and Public Health","funders":"University of Glasgow; British Heart Foundation; Novo Nordisk; Janssen Pharmaceuticals; Merck KGaA; Eli Lilly and Company; AstraZeneca; McKnight Foundation; Sanofi; Diabetes UK; University of Dundee; Amgen","keywords":"Medicine; Metformin; Prediabetes; Diabetes mellitus; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Pioglitazone; Guideline; Endocrinology; Pharmacology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05768202,0.0002901728,0.0007658851,0.001574204,0.001324493,0.004278737,0.002312974,0.00223622,0.003439946],"category_scores_gemma":[0.1578047,0.000534728,0.001381552,0.003788132,0.001618444,0.003253042,0.00271952,0.002016546,0.0004728657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01204304,"about_ca_system_score_gemma":0.02907612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1359285,"about_ca_topic_score_gemma":0.182504,"domain_scores_codex":[0.9237682,0.0369857,0.01066265,0.003773376,0.01925726,0.005552912],"domain_scores_gemma":[0.8413222,0.05647128,0.05742829,0.005375051,0.02892632,0.01047686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008309008,0.0007593281,0.7657083,0.00166616,0.0007283316,0.0005178528,0.01005245,0.00317872,0.0005637845,0.01654242,0.06773061,0.1317213],"study_design_scores_gemma":[0.0007130337,0.001206416,0.89225,0.004131245,0.0003858081,0.0005813538,0.01244792,0.01085974,0.0007456694,0.009851847,0.0665335,0.000293432],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5833361,0.006194432,0.005789063,0.3763509,0.00237835,0.0006658764,0.005000219,0.0001108329,0.02017426],"genre_scores_gemma":[0.9255283,0.001867659,0.006061987,0.0630997,0.001010798,0.0003702564,0.001423927,0.00004800771,0.0005894643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1359285,"threshold_uncertainty_score":0.3050553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05156963613102298,"score_gpt":0.297946433055281,"score_spread":0.246376796924258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}